A New Approach to Staging Diabetic Eye Disease
Ophthalmology Science · 2024-05 · 4 (3) · 100420
DOI: 10.1016/j.xops.2023.100420 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ophthalmology Science, 2024-05. Verfasst von Roomasa Channa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NEI NIH HHS, Research to Prevent Blindness.
Abstract (Originalsprache)
Topic: The goal of this review was to summarize the current level of evidence on biomarkers to quantify diabetic retinal neurodegeneration (DRN) and diabetic macular edema (DME). Clinical relevance: With advances in retinal diagnostics, we have more data on patients with diabetes than ever before. However, the staging system for diabetic retinal disease is still based only on color fundus photographs and we do not have clear guidelines on how to incorporate data from the relatively newer modalities into clinical practice.
Methods
In this review, we use a Delphi process with experts to identify the most promising modalities to identify DRN and DME. These included microperimetry, full-field flash electroretinogram, spectral-domain OCT, adaptive optics, and OCT angiography. We then used a previously published method of determining the evidence level to complete detailed evidence grids for each modality.
Results
Our results showed that among the modalities evaluated, the level of evidence to quantify DRN and DME was highest for OCT (level 1) and lowest for adaptive optics (level 4).
Conclusion
For most of the modalities evaluated, prospective studies are needed to elucidate their role in the management and outcomes of diabetic retinal diseases. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.
- Department of Pediatric Endocrinology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Division of Endocrinology, Vall d'Hebron University Hospital, CIBERDEM, Barcelona, Spain.
- Consultant, Belmont, Massachusetts.
- Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.
- Department of Ophthalmology, University of Alabama, Birmingham, Alabama.
Förderung
- NIDDK NIH HHS
- NEI NIH HHS
- Research to Prevent Blindness
- Juvenile Diabetes Research Foundation United States of America
Zitieren
APA
Channa, R., Wolf, R. M., Simo, R., Brigell, M., Fort, P., Curcio, C., Lynch, S., Verbraak, F., Abramoff, M. D., & Diabetic Retinal Neurodegeneration and Macular Edema working group of the Mary Tyler Moore Vision Initiative’s Diabetic Retinal Disease Staging Update Project (2024). A New Approach to Staging Diabetic Eye Disease. Ophthalmology Science, 4(3), 100420. https://doi.org/10.1016/j.xops.2023.100420
Vancouver
Channa R, Wolf RM, Simo R, Brigell M, Fort P, Curcio C, et al. A New Approach to Staging Diabetic Eye Disease. Ophthalmology Science. 2024;4(3):100420. doi:10.1016/j.xops.2023.100420
BibTeX
@article{Channa2024,
author = {Channa, Roomasa and Wolf, Risa M and Simo, Rafael and Brigell, Mitchell and Fort, Patrice and Curcio, Christine and Lynch, Stephanie and Verbraak, Frank and Abramoff, Michael D and Diabetic Retinal Neurodegeneration and Macular Edema working group of the Mary Tyler Moore Vision Initiative’s Diabetic Retinal Disease Staging Update Project, Diabetic Retinal Neurodegeneration and Macular Edema working group of the Mary Tyler Moore Vision Initiative’s Diabetic Retinal Disease Staging Update Project},
title = {A New Approach to Staging Diabetic Eye Disease},
journal = {Ophthalmology Science},
year = {2024},
volume = {4},
number = {3},
pages = {100420},
doi = {10.1016/j.xops.2023.100420}
}
EUVIMED